EP4267587A2 - Inhibiteurs de peptidylarginine déiminases - Google Patents

Inhibiteurs de peptidylarginine déiminases

Info

Publication number
EP4267587A2
EP4267587A2 EP21848379.0A EP21848379A EP4267587A2 EP 4267587 A2 EP4267587 A2 EP 4267587A2 EP 21848379 A EP21848379 A EP 21848379A EP 4267587 A2 EP4267587 A2 EP 4267587A2
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
alkyl
compound
pharmaceutically acceptable
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21848379.0A
Other languages
German (de)
English (en)
Inventor
Daniel H. BYUN
Eda Y. CANALES
Laurent P. DEBIEN
Petr Jansa
Rick A. Lee
Jennifer A. Loyer-Drew
Stephane Perreault
Hyung-Jung Pyun
Roland D. Saito
Michael S. SANGI
Adam J. Schrier
Marina E. SHATSKIKH
James G. Taylor
Jennifer A. Treiberg
Joshua J. Van Veldhuizen
Lianhong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of EP4267587A2 publication Critical patent/EP4267587A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
  • BACKGROUND Peptidylarginine deiminases catalyze the posttranslational modification of peptidyl arginine to peptidyl citrulline.
  • PAD isozymes with 45% to 58% amino acid sequence identity between human isozymes and at least 70% identity across each vertebrate orthologue. PADs have diverse tissue distribution, different putative physiological functions, and reported associations with various disease states.
  • PAD6 is thought to be the only catalytically inactive PAD and is expressed mainly in oocyte, ovary and early embryo; it is proposed to be involved in oocyte cytoskeletal sheet formation and female fertility.
  • PAD1 and PAD3 are expressed in epidermis and hair follicles and are proposed to be involved in cornification of epidermal tissues, hair growth and maintenance of the stratum corneum.
  • PAD2 is expressed more broadly and can be found in multiple tissues and cell types including brain, spinal cord, skeletal muscles, pituitary glands, spleen, neutrophils and macrophages. It is proposed to be involved in plasticity of CNS, transcription regulation, chemokine signaling, and female reproduction.
  • PAD4 peptidylarginine deiminase type 4
  • X 5 is N or C-R 5
  • X 7 is N or C-R 7
  • R 1 is hydrogen, halo, -CN, -OR 12 , -N(R 12 )2, -SR 12 , C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , C 3-6 cycloalkyl optionally substituted with 1 to 5 Z 1 , or 4-6 membered heterocyclyl optionally substituted with 1 to 5 Z 1
  • R 2 is hydrogen, halo, -CN, -OR 12 , -N(R 12 )2, -SR 12 , -S(O)R 20 , C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , C 3-6 cycloalkyl optionally substituted with 1 to 5 Z 1 , or 4-6 membered heterocyclyl optionally substituted with 1 to 5 Z 1
  • R 3 is hydrogen, -N
  • the present disclosure provides a method of inhibiting peptidylarginine deiminase type 4 (PAD4) comprising contacting an effective amount of a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, with a cell.
  • the present disclosure provides a method of inhibiting peptidylarginine deiminase type 4 (PAD4) comprising administering an effective amount of a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
  • the present disclosure provides a method for treating acute lymphocytic leukemia, ankylosing spondylitis, cancer, chronic lymphocytic leukemia, colitis, lupus, systemic lupus erythematosus, cutaneous lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or ulcerative colitis, comprising administering an effective amount of a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
  • the present disclosure provides a pharmaceutical composition comprising a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
  • the present disclosure provides a pharmaceutical composition comprising a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent and at least one pharmaceutically acceptable carrier or excipient.
  • the present disclosure provides a pharmaceutical composition comprising a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, at least one additional therapeutic agent suitable for treating rheumatoid arthritis, and at least one pharmaceutically acceptable carrier or excipient.
  • the present disclosure provides a kit that includes a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, a label and/or instructions for use of the compound in the treatment of rheumatoid arthritis or a disease or condition mediated by peptidylarginine deiminase type 4 (PAD4).
  • PAD4 peptidylarginine deiminase type 4
  • the present disclosure provides a compound of Formula I, or any formula described herein, or a pharmaceutically acceptable salt thereof, for use in therapy.
  • the compound includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art, and so forth.
  • a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(O)NH2 is attached through the carbon atom.
  • a dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.
  • a wavy line on a chemical group as shown below, for example, indicates a point of attachment, i.e., it shows the broken bond by which the group is connected to another described group.
  • the prefix “Cu-v” indicates that the following group has from u to v carbon atoms.
  • C1-6 alkyl indicates that the alkyl group has from 1 to 6 carbon atoms.
  • Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.
  • the term “about” includes the indicated amount ⁇ 10%.
  • the term “about” includes the indicated amount ⁇ 5%.
  • the term “about” includes the indicated amount ⁇ 1%.
  • alkyl has 1 to 20 carbon atoms (i.e., C1-20 alkyl), 1 to 12 carbon atoms (i.e., C1-12 alkyl), 1 to 10 carbon atoms (i.e., C1-10 alkyl), 1 to 8 carbon atoms (i.e., C 1-8 alkyl), 1 to 6 carbon atoms (i.e., C1-6 alkyl), or 1 to 4 carbon atoms (i.e., C 1-4 alkyl).
  • alkyl groups include methyl, ethyl, propyl, isopropyl, n- butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl.
  • butyl includes n-butyl (i.e., -(CH 2 ) 3 CH 3 ), sec-butyl (i.e., -CH(CH 3 )CH 2 CH 3 ), isobutyl (i.e., -CH 2 CH(CH 3 ) 2 ) and tert-butyl (i.e., - C(CH 3 ) 3 ); and “propyl” includes n-propyl (i.e., -(CH 2 ) 2 CH 3 ) and isopropyl (i.e., -CH(CH 3 ) 2 ).
  • alkenyl refers to any group derived from a straight or branched hydrocarbon with at least one carbon-carbon double bond. Unless otherwise specified, alkenyl groups have from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 12 carbon atoms (i.e., C 2-12 alkenyl), 2 to 10 carbon atoms (i.e., C 2-10 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl).
  • alkynyl groups include, but are not limited to, ethynyl (-C ⁇ C-), propargyl (-CH 2 C ⁇ C- ), (E)-pent-3-en-1-ynyl, and the like.
  • aryl refers to a single all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic.
  • an aryl group 6 to 20 ring carbon atoms i.e., C6-20 aryl
  • 6 to 14 carbon ring atoms i.e., C6-14 aryl
  • 6 to 12 carbon ring atoms i.e., C6-12 aryl
  • 6 to 10 carbon ring atoms i.e., C6-10 aryl
  • Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 20 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e., carbocycle).
  • a 6-membered aryl would include phenyl and a 10- membered aryl would include naphthyl and 1,2,3,4-tetrahydronaphthyl.
  • Aryl groups include, but are not limited to, those groups derived from acenaphthylene, anthracene, azulene, benzene, chrysene, a cyclopentadienyl anion, naphthalene, fluoranthene, fluorene, indane, perylene, phenalene, phenanthrene, pyrene, and the like.
  • Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, and the like.
  • cycloalkyl refers to a single saturated or partially unsaturated all carbon ring having 3 to 20 annular carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 14 ring carbon atoms (i.e., C 3-14 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 cycloalkyl).
  • cycloalkenyl refers to the non-aromatic carbocyclic (partially saturated cyclic alkyl) group having at least one double bond.
  • cycloalkyl includes multicyclic carbocycles such as a bicyclic carbocycles (e.g., bicyclic carbocycles having about 6 to 12 annular carbon atoms such as bicyclo[3.1.0]hexane, bicyclo[2.1.1]hexane), bicyclo[1.1.1]pentane, and polycyclic carbocycles (e.g., tricyclic and tetracyclic carbocycles with up to about 20 annular carbon atoms).
  • bicyclic carbocycles e.g., bicyclic carbocycles having about 6 to 12 annular carbon atoms such as bicyclo[3.1.0]hexane, bicyclo[2.1.1]hexane), bicyclo[1.1.1]pentane
  • polycyclic carbocycles e.g.,
  • Haloalkyl refers to an alkyl group as defined herein, wherein one or more hydrogen atoms (e.g., 1-5, or 1-3) are replaced by a halogen. Examples include, but are not limited to, –CH2Cl, –CH2F, – CH2Br, –CFClBr, –CH2CH2Cl, –CH2CH2F, –CF3, –CH2CF3, –CH2CCl3, and the like, as well as alkyl groups such as perfluoroalkyl in which all hydrogen atoms are replaced by fluorine atoms.
  • Heteroalkyl groups include, but are not limited to, -OCH3, -CH2OCH3, -SCH3, -CH2SCH3, -NRCH3, -CH2NRCH3, -CH2OH and the like, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl.
  • heteroalkyl includes 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
  • Heteroaryl refers to a monoradical or diradical aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • the term includes fused ring systems wherein one or more (e.g., one, two, or three) fused rings is/are fully or partially unsaturated.
  • heteroaryl include 1 to 20 ring carbon atoms (i.e., C 1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C 3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C 3-8 heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur.
  • heteroaryl groups include, but are not limited to, groups derived from acridine, benzimidazole, benzothiophene, benzofuran, benzoxazole, benzothiazole, carbazole, carboline, cinnoline, furan, imidazole, imidazopyridine, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyridone, pyrimidine, pyrrole, pyr
  • Heterocyclyl refers to a saturated or unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur.
  • the term “heterocyclyl” includes heterocycloalkenyl groups (i.e. the heterocyclyl group having at least one double bond), bridged- heterocyclyl groups, fused-heterocyclyl groups, and spiro-heterocyclyl groups.
  • a heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro.
  • heterocyclyl Any non- aromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom).
  • heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aryl or heteroaryl ring, regardless of the attachment to the remainder of the molecule.
  • heterocyclyl has 2 to 20 ring carbon atoms, 2 to 12 ring carbon atoms, 2 to 10 ring carbon atoms, 2 to 8 ring carbon atoms, 3 to 12 ring carbon atoms, 3 to 8 ring carbon atoms, or 3 to 6 ring carbon atoms; and having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen.
  • a heterocyclyl may contain one or more oxo and/or thioxo groups.
  • heterocyclyl groups include, but are not limited to, groups derived from azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, tetrahydro-2H-thiopyran 1,1- dioxide, quinuclidine, N-bromopyrrolidine, N-chloropiperidine, and the like.
  • Heterocycles include spirocycles, such as, for example, aza or oxo- spiroheptanes.
  • bridged- heterocyclyl refers to a four- to ten-membered cyclic moiety connected at two non-adjacent atoms of the heterocyclyl with one or more (e.g., 1 or 2) four- to ten-membered cyclic moiety having at least one heteroatom where each heteroatom is independently selected from nitrogen, oxygen, and sulfur.
  • bridged- heterocyclyl includes bicyclic and tricyclic ring systems.
  • spiro-heterocyclyl refers to a ring system in which a three- to ten-membered heterocyclyl has one or more additional ring, wherein the one or more additional ring is three- to ten- membered cycloalkyl or three- to ten-membered heterocyclyl, where a single atom of the one or more additional ring is also an atom of the three- to ten-membered heterocyclyl.
  • spiro- heterocyclyl rings examples include bicyclic and tricyclic ring systems, such as 2-oxa-7-azaspiro[3.5]nonanyl, 2- oxa-6-azaspiro[3.4]octanyl, 5-azaspiro[2.4]heptanyl, and 6-oxa-1-azaspiro[3.3]heptanyl.
  • fused-heterocyclyl rings include, but are not limited to, 3-azabicyclo[3.1.0]hexanyl, 1,2,3,4- tetrahydroisoquinolinyl, 1-oxo-1,2,3,4-tetrahydroisoquinolinyl, 1-oxo-1,2-dihydroisoquinolinyl, 4,5,6,7- tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.
  • groups derived from include dihydroquinolines, e.g., 3,4-dihydroquinoline, dihydroisoquinolines, e.g., 1,2-dihydroisoquinoline, dihydroimidazole, tetrahydroimidazole, etc., indoline, isoindoline, isoindolones (e.g., isoindolin-1-one), isatin, dihydrophthalazine, quinolinone, spiro[cyclopropane-1,1'-isoindolin]-3'-one, and the like.
  • dihydroquinolines e.g., 3,4-dihydroquinoline
  • dihydroisoquinolines e.g., 1,2-dihydroisoquinoline, dihydroimidazole, tetrahydroimidazole, etc.
  • indoline isoindoline
  • isoindolones e.g., is
  • heterocycles include, but are not limited to, groups derived from 2- azabicyclo[2.2.1]heptane, 8-azabicyclo[3.2.1]octane, 3-azabicyclo[4.1.0]heptane, octahydro-2H- pyrido[4,3-b][1,4]oxazine, hexahydropyridazine, 3,8-diazabicyclo[3.2.1]octane, 2,5- diazabicyclo[2.2.1]heptane, 3,6-diazabicyclo[3.1.1]heptane, 3-oxa-7,9-diazabicyclo[3.3.1]nonane, 7- azabicyclo[2.2.1]heptane, 2-azabicyclo[2.2.2]octane, 6-oxa-2-azabicyclo[3.2.1]octane, and hexahydropyrazino[2,1-c][1,4
  • “Bridged” refers to a ring fusion wherein non-adjacent atoms on a ring are joined by a divalent substituent, such as an alkylene or heteroalkylene group or a single heteroatom. Quinuclidinyl and adamantyl are examples of bridged ring systems.
  • “Spiro” refers to a ring substituent which is joined by two bonds at the same carbon atom. Examples of spiro groups include 1,1-diethylcyclopentane, dimethyl-dioxolane, and 4-benzyl-4- methylpiperidine, wherein the cyclopentane and piperidine, respectively, are the spiro substituents.
  • substituents bound to the same atom join together (e.g., two Z 8 groups join together) they may be taken from the same point of attachment to form a spiro ring.
  • the term “fused” refers to a ring which is bound to an adjacent ring.
  • “Hydroxyl” and “hydroxy” are used interchangeably and refer to – OH. Where tautomeric forms of the compound exist, hydroxyl and oxo groups are interchangeable. It is understood that combinations of chemical groups may be used and will be recognized by persons of ordinary skill in the art. For instance, the group “hydroxyalkyl” would refer to a hydroxyl group attached to an alkyl group.
  • substituent combinations used herein include: C 1-6 alkylamiocarbonyl (e.g., CH 3 CH 2 NHC(O)-), C 1-6 alkoxycarbonyl (e.g., CH 3 O-C(O)-), 5-7 membered heterocyclyl-C 1-6 alkyl (e.g., piperazinyl-CH 2 -), C 1-6 alkylsulfonyl-5-7 membered heterocyclyl (e.g., CH 3 S(O) 2 -morpholinyl-), 5-7 membered heterocyclyl C 1-6 alkoxy, 5-7 membered heterocyclyloxy, (4-7 membered heterocyclyl)-4-7 membered heterocyclyl (e.g., oxetanyl-pyrrolidinyl-), C 3-6 cycloalkylaminocarbonyl (e.g., cyclopropyl- NH-C(O)-),
  • a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc.
  • a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc.
  • the suffix “ene” is often used to refer to a group that has two single bond points of attachments to other groups. For example, methylene refers to -CH 2 -.
  • Diastereoisomers are stereoisomers that have at least two stereocenters, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
  • the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included. To the extent that compounds depicted herein are represented as having a particular stereochemistry, it is understood by one of skill in the art that such compounds may contain some detectable or undetectable levels of compounds sharing the same structure, but having different stereochemistry. “IC 95 ” or “EC 95 ” refers to the inhibitory concentration required to achieve 95% of the maximum desired effect, which in many cases herein is the inhibition of the PAD4 enzyme.
  • IC 50 or “EC 50 ” refers to the inhibitory concentration required to achieve 50% of the maximum desired effect, which in many cases herein is the inhibition of the PAD4 enzyme.
  • “Pharmaceutically acceptable” refers to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
  • “Pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • “Pharmaceutically acceptable salt” refers to a salt of a compound that is pharmaceutically acceptable and that possesses (or can be converted to a form that possesses) the desired pharmacological activity of the parent compound.
  • Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, lactic acid, maleic acid, malonic acid, mandelic acid, methanesulfonic acid, 2-napththalenesulfonic acid, oleic acid, palmitic acid, propionic acid, stearic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, and the like, and salts formed when an acidic proton present in the parent compound is replaced by either a metal ion, e.g., an alkali metal ion, an alkaline
  • n is the number of hydrogen atoms in the molecule.
  • the deuterium atom is a non-radioactive isotope of the hydrogen atom.
  • Such compounds exhibit may increase resistance to metabolism, and thus may be useful for increasing the half-life of the compounds when administered to a mammal. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci., 5(12):524-527 (1984).
  • Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms have been replaced by deuterium.
  • Any formula or structure given herein, including Formula I, or any formula disclosed herein, is intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more (e.g., one to three, or one to five) atoms are replaced by an isotope having a selected atomic mass or mass number.
  • isotopes examples include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to 2 H (deuterium, D), 3 H (tritium), 11 C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 Cl, and 125 I.
  • isotopically labeled compounds of the present disclosure for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are within the ambit of the present disclosure.
  • Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • Such isotopically labeled analogs of compounds of the present disclosure may also be useful for treatment of diseases disclosed herein because they may provide improved pharmacokinetic and/or pharmacodynamic properties over the unlabeled forms of the same compounds.
  • Such isotopically leveled forms of or analogs of compounds herein are within the ambit of the present disclosure.
  • prodrugs of the compounds disclosed herein are defined in the pharmaceutical field as a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway.
  • PAD4 peptidylarginine deiminase type 4
  • X 5 is N or C-R 5 ;
  • X 7 is N or C-R 7 ;
  • R 1 is hydrogen, halo, -CN, -OR 12 , -N(R 12 )2, -SR 12 , C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , C 3-6 cycloalkyl optionally substituted with 1 to 5 Z 1 , or 4-6 membered heterocyclyl optionally substituted with 1 to 5 Z 1 ;
  • R 2 is hydrogen, halo, -CN, -OR 12 , -N(R 12 )2, -SR 12 , -S(O)R 20 , C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , C 3-6 cycloalkyl optionally substituted with 1 to 5 Z 1 , or 4-6 membered heterocyclyl optionally substituted with 1 to 5 Z 1 ;
  • R 3 is hydrogen, -N(
  • X 5 is N. In certain embodiments, X 5 is C-R 5 . In certain embodiments, X 5 is C-H or C-F. In certain embodiments, X 7 is N. In certain embodiments, X 7 is C-R 7 . In certain embodiments, X 7 is C-H or C-F. In certain embodiments, R 8 is hydrogen. Also provided is a compound of Formula IB: wherein each of R 1 , R 2 , R 3 , R 4 , R 6 , R 10 , and R 11 are independently as defined herein. In certain embodiments, R 1 is hydrogen, halo or -C 1-8 alkyl optionally substituted with 1 to 3 Z 1 .
  • R 1 is hydrogen, halo or -C 1-8 alkyl. In certain embodiments, R 1 is hydrogen or halo. In certain embodiments, R 1 is hydrogen, fluoro or methyl. In certain embodiments, R 1 is hydrogen or fluoro. In certain embodiments, R 1 is hydrogen. In certain embodiments, R 2 is hydrogen, halo, -OR 12 , -N(R 12 )2, -SR 20 , -S(O)R 20 , C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , C 3-6 cycloalkyl optionally substituted with 1 to 5 Z 1 . In certain embodiments, R 2 is hydrogen, halo, or -O-C 1-8 alkyl.
  • R 2 is hydrogen, fluoro, methyl, ethyl, -CHF2, -OH, -OCH3, -SH, -SCH3, -S(O)CH3, cyclopropyl, -NHCH3, -N(CH3)2, or 2-cyanopyrimidin-5-oxy.
  • R 2 is hydrogen, methyl, ethyl, -CHF2, -OH, -OCH3, -SH, -SCH3, -S(O)CH3, cyclopropyl, - NHCH3, -N(CH3)2, or 2-cyanopyrimidin-5-oxy.
  • R 2 is hydrogen, fluoro, chloro, or methoxy.
  • R 2 is fluoro, chloro, or methoxy. In certain embodiments, R 2 is hydrogen, fluoro, or -OCH3. In certain embodiments, R 2 is hydrogen or -OCH3. In certain embodiments, R 2 is -O-C 1-8 alkyl. In certain embodiments, R 2 is methoxy. In certain embodiments, R 2 is halo. In certain embodiments, R 2 is halo. In certain embodiments, R 2 is fluoro and chloro. In certain embodiments, R 2 is fluoro. In certain embodiments, R 2 is hydrogen or fluoro. In certain embodiments, R 2 is hydrogen.
  • R 3 is hydrogen, C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , or C 3-10 cycloalkyl optionally substituted with 1 to 5 Z 1 . In certain embodiments, R 3 is C 1-8 alkyl optionally substituted with 1 to 5 Z 1 or C 3-10 cycloalkyl optionally substituted with 1 to 5 Z 1 . In certain embodiments, R 3 is C 1-8 alkyl optionally substituted with 1 to 5 Z 1 . In certain embodiments, R 3 is C 3-10 cycloalkyl optionally substituted with 1 to 5 Z 1 .
  • R 3 is methyl, ethyl, isopropyl, CHF 2 , -NH 2 , , , , , In certain embodiments, R 3 is methyl or cyclopropyl.
  • R 2 is hydrogen, halo, -CN, -OR 12 , -N(R 12 )2, -SR 12 , -C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , C 3-6 cycloalkyl optionally substituted with 1 to 5 Z 1 , or 4-6 membered heterocyclyl optionally substituted with 1 to 5 Z 1 ; and R 3 is hydrogen, C 1-8 alkyl optionally substituted with 1 to 5 Z 1 , C 3-10 alkenyl optionally substituted with 1 to 5 Z 1 , C 3-10 alkynyl optionally substituted with 1 to 5 Z 1 , C 3-10 cycloalkyl optionally substituted with 1 to 5 Z 1 , or 4-10 membered heterocycly
  • R 4 is C3-10 cycloalkyl optionally substituted with 1 to 5 Z 1 .
  • R 4 is hydrogen, methyl, ethyl, , , , , , , , In certain embodiments, R 4 is hydrogen, methyl, ethyl, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
  • R 4 is In certain embodiments, R 6 is -N(R 14 )S(O)2R 9 , -N(R 14 )C(O)OR 9 , -OC(O)R 9 , or -OC(O)OR 9 . In certain embodiments, R 6 is -N(R 14 )S(O)2R 9 . In certain embodiments, R 6 is -N(R 14 )C(O)OR 9 . In certain embodiments, R 6 is -OC(O)R 9 . In certain embodiments, R 6 is -OC(O)OR 9 .
  • R 6 is -N(R 14 )C(O)OR 9 , -OC(O)R 9 , or -OC(O)OR 9 .
  • L is C 1-8 alkylene, -O-C 1-8 alkylene, C 1-8 haloalkylene, -O-C 1-8 haloalkylene, or 5-10 membered heteroarylene; and each C 1-8 alkylene, C 1-8 haloalkylene, or 5-10 membered heteroarylene of L is optionally substituted with 1 to 5 Z 1 ;
  • R 6 is -L-R 13 ; wherein L is C 1-8 alkylene, -O- C 1-8 alkylene, C 1-8 haloalkylene, -O-C 1-8 haloalkylene, or 5-10 membered heteroarylene; and each C 1-8 alkylene, C 1-8 haloalkylene, or 5-10 membered heteroarylene of L is optionally substituted with 1 to 5 Z 1
  • R 6 is -L-R 13 ; wherein L is C 1-8 alkylene, C 1-8 haloalkylene, or 5-10 membered heteroarylene; and each C 1-8 alkylene, C 1-8 haloalkylene, or 5-10 membered heteroarylene of L is optionally substituted with 1 to 5 Z 1 ; and R 13 is -N(R 15 )(R 14 ), -C(O)N(R 14 )2, -N(R 14 )C(O)R 9 , - N(R 14 )C(O)OR 9 , -N(R 14 )C(O)N(R 14 ) 2 , or -N(R 14 )S(O) 2 R 9 .
  • R 6 is -OR 15 , C 2-8 alkenyl optionally substituted with 1 to 5 Z 1 , C 2-8 alkynyl optionally substituted with 1 to 5 Z 1 , C 3-10 cycloalkyl substituted with 1 to 5 Z 1 , C 6-10 aryl substituted with 1 to 5 Z 1 , or 4-10 membered heterocyclyl substituted with 1 to 5 Z 1 ; and R 15 is cycloalkyl optionally substituted with 1 to 5 Z 1 , 4-10 membered heterocyclyl optionally substituted with 1 to 5 Z 1 , C 6-10 aryl optionally substituted with 1 to 5 Z 1 , or 5-10 membered heteroaryl optionally substituted with 1 to 5 Z 1 .
  • R 6 is -OR 15 ; and R 15 is cycloalkyl optionally substituted with 1 to 5 Z 1 , 4-10 membered heterocyclyl optionally substituted with 1 to 5 Z 1 , C 6-10 aryl optionally substituted with 1 to 5 Z 1 , or 5-10 membered heteroaryl optionally substituted with 1 to 5 Z 1 .
  • R 6 is C 2-8 alkenyl optionally substituted with 1 to 5 Z 1 .
  • R 6 is C 2-8 alkynyl optionally substituted with 1 to 5 Z 1 .
  • R 6 is C 3-10 cycloalkyl substituted with 1 to 5 Z 1 .
  • R 6 is C 6-10 aryl substituted with 1 to 5 Z 1 . In certain embodiments, R 6 is 4-10 membered heterocyclyl substituted with 1 to 5 Z 1 . In certain embodiments, R 6 is , , , or ; wherein q is 0, 1 or 2; and n is 0, 1, 2, 3, 4, 5, or 6. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, R 6 is ; wherein q is 0, 1 or 2; and n is 0, 1, 2, 3, 4, 5, or 6. In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2.
  • n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, n is 4. In certain embodiments, n is 5. In certain embodiments, n is 6. In certain embodiments, n is 0, 1, 2, 3, or 4. In certain embodiments, n is 0, 1, or 2. In certain embodiments, R 6 is -Cl, -CN,
  • R 6 is In certain embodiments, R 6 is , , , , , , , In certain embodiments, R 6 is , , , , , , In certain embodiments, R 6 is , , , , , , , In certain embodiments, R 6 is 5 , , , In certain embodiments, R 6 is , , , , , , ,
  • R 6 is , , , ,
  • R 6 is In certain embodiments, R 6 is , , o . In certain embodiments, R 6 is , , In certain embodiments, R 6 is In certain embodiments, R 6 is , , , , In certain embodiments, R 7 is hydrogen. In certain embodiments, R 8 is hydrogen.
  • R 10 is hydrogen, C 1-8 alkyl optionally substituted with 1 to 3 Z 10 , or C 3-6 cycloalkyl optionally substituted with 1 to 3 Z 10 ;
  • R 11 is C 1-8 alkyl optionally substituted with 1 to 4 Z 10 , C3-8 cycloalkyl optionally substituted with 1 to 4 Z 10 , or 4-12-membered heterocyclyl optionally substituted with 1 to 4 Z 10 ; or R 10 and R 11 are taken together with the nitrogen to which they are attached to form a 4-12- membered heterocyclyl optionally substituted with 1 to 4 Z 10 .
  • R 10 is hydrogen or -CH3, and R 11 is C1-6 alkyl optionally substituted with 1 to 3 Z 10 , C 3-6 cycloalkyl optionally substituted with 1 to 3 Z 10 , or 4-12-membered heterocyclyl optionally substituted with 1 to 3 Z 10 ; or R 10 and R 11 taken together form a 4-10-membered heterocyclyl optionally substituted with 1 to 3 Z 10 .
  • R 10 is hydrogen or -CH 3
  • R 11 is 4-12 membered heterocyclyl optionally substituted with 1 to 3 Z 10 .
  • R 10 and R 11 taken together with the nitrogen to which they are attached form a 4-10 membered heterocyclyl optionally substituted with 1 to 3 Z 10 .
  • provided is compound is represented by Formula IC: wherein each of n, R 1 , R 2 , R 3 , R 4 , X 5 , R 10 , R 11 , and R 17 are independently as defined herein.
  • provided is compound is represented by Formula ID: wherein each R 18 is independently hydrogen or Z 1 ; and each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 10 , R 11 , and R 14 are independently as defined herein.
  • provided is compound is represented by Formula IE: wherein each R 18 is independently hydrogen or Z 1 ; and each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 10 , R 11 , and R 14 are independently as defined herein.
  • provided is compound is represented by Formula IF: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 10 , R 11 , and R 14 are independently as defined herein.
  • provided is compound is represented by Formula IG: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , and R 6 are independently as defined herein.
  • provided is compound is represented by Formula IH: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , and R 6 are independently as defined herein.
  • provided is compound is represented by Formula IJ: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , and R 6 are independently as defined herein.
  • provided is compound is represented by Formula IK: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , and R 6 are independently as defined herein.
  • provided is compound is represented by Formula IL: wherein each of Z 10 , R 1 , R 2 , R 3 , R 4 , X 5 , and R 6 are independently as defined herein.
  • provided is compound is represented by Formula IM: wherein each of Z 10 , R 10 , R 1 , R 2 , R 3 , R 4 , X 5 , and R 6 are independently as defined herein.
  • provided is compound is represented by Formula IN: wherein each of Z 10 , R 10 , R 1 , R 2 , R 3 , R 4 , X 5 , and R 6 are independently as defined herein.
  • R 4 is C 1-8 alkyl optionally substituted with 1 to 3 Z 1 or C 3-10 cycloalkyl optionally substituted with 1 to 3 Z 1 . In certain embodiments, R 4 is C 1-8 alkyl optionally substituted with 1 to 3 Z 1 . In certain embodiments, R 4 is C 3-10 cycloalkyl optionally substituted with 1 to 3 Z 1 .
  • R 4 is ethyl, In certain embodiments, R 4 is In certain embodiments, the moiety , . In certain embodiments, the moiety In certain embodiments, the moiety In certain embodiments, the moiety is . In certain embodiments, the moiety In certain embodiments, provided is compound is represented by Formula IP: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 14 and R 18 are independently as defined herein. In certain embodiments, provided is compound is represented by Formula IQ: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 14 and R 18 are independently as defined herein.
  • provided is compound is represented by Formula IR: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 14 and R 18 are independently as defined herein.
  • provided is compound is represented by Formula IS: IS wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 14 and R 18 are independently as defined herein.
  • provided is compound is represented by Formula IT: wherein each of Z 10 , R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 14 and R 18 are independently as defined herein.
  • provided is compound is represented by Formula IU: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 14 and R 18 are independently as defined herein.
  • provided is compound is represented by Formula IV: V wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , R 14 and R 18 are independently as defined herein.
  • each R 18 is independently hydrogen, or Z 1 .
  • each R 18 is independently hydrogen, C 1-8 alkyl optionally substituted with 1 to 5 Z 1a , C2-8 alkenyl optionally substituted with 1 to 5 Z 1a , C2-8 alkynyl optionally substituted with 1 to 5 Z 1a , C3-10 cycloalkyl optionally substituted with 1 to 5 Z 1a , 4-10 membered heterocyclyl optionally substituted with 1 to 5 Z 1a , C6-10 aryl optionally substituted with 1 to 5 Z 1a , or 5-10 membered heteroaryl optionally substituted with 1 to 5 Z 1a . In certain embodiments, each R 18 is independently hydrogen or C 1-8 alkyl optionally substituted with 1 to 5 Z 1 .
  • each R 18 is independently hydrogen or C 1-8 alkyl optionally substituted with 1 to 5 halo. In certain embodiments, each R 18 is independently hydrogen or C 1-8 alkyl. In certain embodiments, each R 18 is independently hydrogen or methyl. In certain embodiments, one R 18 is hydrogen and the other is methyl. In certain embodiments, each R 18 is methyl. In certain embodiments, each R 18 is hydrogen. In certain embodiments, provided is compound is represented by Formula IW: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , and R 14 are independently as defined herein.
  • provided is compound is represented by Formula IX: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , and R 14 are independently as defined herein.
  • provided is compound is represented by Formula IY: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , and R 14 are independently as defined herein.
  • provided is compound is represented by Formula IZ: wherein each of R 1 , R 2 , R 3 , R 4 , X 5 , R 9 , and R 14 are independently as defined herein.
  • R 14 is hydrogen or C 1-8 alkyl optionally substituted with 1 to 5 Z 1 .
  • R 14 is hydrogen.
  • R 20 is hydrogen or C 1-8 alkyl optionally substituted by 1 to 3 Z 1a .
  • R 20 is hydrogen or C 1-8 alkyl.
  • R 20 is hydrogen or methyl.
  • R 20 is methyl.
  • R 20 is hydrogen.
  • each Z 1 is independently halo, -NO2, -N3, -CN, C 1-8 alkyl optionally substituted by 1 to 5 Z 1b , C2-8 alkenyl optionally substituted by 1 to 5 Z 1b , C2-8 alkynyl optionally substituted by 1 to 5 Z 1b , C3-10 cycloalkyl optionally substituted by 1 to 5 Z 1b , 6-10 membered aryl optionally substituted by 1 to 5 Z 1b , 4-10 membered heterocyclyl optionally substituted by 1 to 5 Z 1b , 5- 10 membered heteroaryl optionally substituted with 1 to 5 Z 1b , -OR 21 , -C(O)R 21 , - C(O)OR 21 , -C(O)N(R 21 )2, -N(R 21 )2, -N(R 21 )3 + , -N(R 21 )C(O)R 21 , -N(R 21 )
  • each Z 1 is independently oxo, hydroxy, fluoro, chloro, -CN, -CH 3 , ethyl, isopropyl, tert-butyl, -CF 3 , -CHF 2 , cyclopropyl, cyclobutyl, -OCH 3 , -O-ethyl, -O-isopropyl, -O- cyclopropyl, -OCF3, -OCF2H, -C(O)-alkyl, -C(O)-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, or -NH2.
  • each Z 1 is independently halo, oxo, -CN, C1-6 alkyl optionally substituted by 1 to 3 Z 1a , C 3-6 cycloalkyl optionally substituted with 1 to 3 Z 1b , 4-6 membered heterocyclyl having 1 to 2 heteroatoms selected from O and N that is optionally substituted by 1 to 3 Z 1a , 5-6 membered heteroaryl having 1 to 4 heteroatoms selected from O and N and optionally substituted with 1 to 3 Z 1a , -OR 12 , -N(R 12 )2, -C(O)R 12 , N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )S(O)2R 12 , - OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )2, or -S(O)2R 12 .
  • each Z 1 is independently fluoro, chloro, -CN, C1-6 alkyl optionally substituted with 1 to 3 Z 1b , C 3-6 cycloalkyl optionally substituted by 1 to 3 Z 1b , -OR 12 , -N(R 12 )2, -C(O)R 12 , N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )S(O)2R 12 , -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )2, or -S(O)2R 12 .
  • each Z 1 is independently oxo, hydroxy, fluoro, chloro, -CN, -CH3, ethyl, isopropyl, tert-butyl, -CF3, -CHF2, cyclopropyl, cyclobutyl, -OCH3, -O-ethyl, -O-isopropyl, -O- cyclopropyl, -OCF3, -OCF2H, -C(O)-alkyl, -C(O)-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, or -NH2.
  • each Z 1 is independently halo, oxo, -CN, C 1-6 alkyl optionally substituted by 1 to 3 Z 1a , C 3-6 cycloalkyl optionally substituted with 1 to 3 Z 1b , 4-6 membered heterocyclyl having 1 to 2 heteroatoms selected from O and N that is optionally substituted by 1 to 3 Z 1a , 5-6 membered heteroaryl having 1 to 4 heteroatoms selected from O and N and optionally substituted with 1 to 3 Z 1a , -OR 12 , -N(R 12 ) 2 , -C(O)R 12 , N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )S(O) 2 R 12 , - OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 ) 2 , or -S(O) 2 R 12 ,
  • each Z 1 is independently halo, oxo, -CN, C 1-6 alkyl optionally substituted by 1 to 3 Z 1a , C 3-6 cycloalkyl optionally substituted with 1 to 3 Z 1b , 4-6 membered heterocyclyl having 1 to 2 heteroatoms selected from O and N that is optionally substituted by 1 to 3 Z 1a , 5-6 membered heteroaryl having 1 to 4 heteroatoms selected from O and N and optionally substituted with 1 to 3 Z 1a , -OR 12 , -N(R 12 ) 2 , -C(O)R 12 , N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )S(O) 2 R 12 , - OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 ) 2 , or -S(O) 2 R 12 ,
  • each Z 1 is independently oxo, hydroxy, fluoro, chloro, -CN, -CH 3 , ethyl, isopropyl, tert-butyl, -CF 3 , -CHF 2 , cyclopropyl, cyclobutyl, -OCH 3 , -O-ethyl, -O-isopropyl, -O- cyclopropyl, -OCF3, -OCF2H, -C(O)-alkyl, -C(O)-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, or -NH2.
  • each Z 1 is independently oxo, hydroxy, fluoro, chloro, -CN, -CH3, ethyl, isopropyl, tert-butyl, -CF3, -CHF2, cyclopropyl, cyclobutyl, -OCH3, -O-ethyl, -O-isopropyl, -O- cyclopropyl, -OCF3, -OCF2H, -C(O)-alkyl, -C(O)-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, or -NH2.
  • each Z 1 is independently halo, oxo, -CN, C1-6 alkyl optionally substituted by 1 to 3 Z 1a , C 3-6 cycloalkyl optionally substituted with 1 to 3 Z 1b , 4-6 membered heterocyclyl having 1 to 2 heteroatoms selected from O and N that is optionally substituted by 1 to 3 Z 1a , 5-6 membered heteroaryl having 1 to 4 heteroatoms selected from O and N and optionally substituted with 1 to 3 Z 1a , -OR 12 , -N(R 12 ) 2 , -C(O)R 12 , N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )S(O) 2 R 12 , - OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 ) 2 , or -S(O) 2 R 12 .
  • each Z 1 is independently halo, C 1-8 alkyl optionally substituted by 1 to 3 Z 1a , or -OR 9 . In certain embodiments, each Z 1 is independently halo, C 1-8 alkyl, C 1-8 haloalkyl, or -O-C 1-8 alkyl. In certain embodiments, each Z 1 is independently fluoro, methyl, -CF 3 , or -O-CH 3 .
  • each Z 1a is independently halo, -CN, C 1-6 alkyl optionally substituted by 1 to 3 Z 1b , C 3-6 cycloalkyl optionally substituted by 1 to 3 Z 1b , 6 membered aryl optionally substituted by 1 to 3 Z 1b , 4-6 membered heterocyclyl having 1 to 2 heteroatoms selected from O or N that is optionally substituted by 1 to 3 Z 1b , 5-6 membered heteroaryl having 1 to 2 heteroatoms selected from O and N and optionally substituted with 1 to 3 Z 1b , -OR 12 , -N(R 12 ) 2 , -C(O)R 12 , N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 , - N(R 12 )S(O) 2 R 12 , -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 ,
  • each Z 1a is independently halo, -CH 3 , cyclopropyl, or -OCH 3 .
  • each Z 1b is independently hydroxy, halo, -CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 3-6 cycloalkyl, C1-6 haloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl,, or -O(C1-6 alkyl).
  • a compound as shown in Table 1, or a pharmaceutically acceptable salt thereof Table 1 a]pyridin-2-yl]pyrrolo[2,3-b]pyridin-6- yl]ethyl]-3-fluorobicyclo[1.1.1]pentane- 1-carboxamide fluorobicyclo[1.1.1]pentane-1- carboxamide carboxamide fluorobicyclo[1.1.1]pentane-1- carboxamide ]py y] y] fluorobicyclo[1.1.1]pentane-1- carboxamide fluorobicyclo[1.1.1]pentane-1- carboxamide Ex Structure Name ⁇ N ⁇ -[(1 ⁇ R ⁇ )-1-[2-[7- [(1 ⁇ R ⁇ ,2 ⁇ S ⁇ ,3 ⁇ R ⁇ ,5 ⁇ S ⁇ )-2-amino- 3-methoxy-8-azabicyclo[3.2.1]octane-8- carbonyl]-5-methoxy-3- 22 methylimidazo[1,
  • “Patient” and “subject” refer to humans, domestic animals (e.g., dogs and cats), farm animals (e.g., cattle, horses, sheep, goats and pigs), laboratory animals (e.g., mice, rats, hamsters, guinea pigs, pigs, pocket pets, rabbits, dogs, and monkeys), and the like.
  • the patient is a human.
  • Protein arginine deiminases have been contemplated to display some level of substrate specificity possibly related to their tissue specific expression pattern.
  • a method of treating or preventing rheumatoid arthritis (RA) comprising administering a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, is provided.
  • a method of treating RA comprising administering a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, is provided.
  • a compound described herein may be combined with a 14-3-3 protein eta inhibitor, such as anti-AGX-020 mAbs (rheumatoid arthritis) or Augurex; a 5-Lipoxygenase inhibitor, such as darbufelone, tebufelone, ZD-2138, etalocib, PGV-20229, L-708780, T-0757, T-0799, ZM- 216800, L-699333, BU-4601A, or SKF-104351; a 5-Lipoxygenase/Cyclooxygenase inhibitor, such as tenoxicam, licofelone, tenidap, tepoxalin, flobufen, SKF-86002, WY-28342, or CI-986; or a 5- Lipoxygenase/PPAR gamma agonist, such as etalocib; a Abl tyl et
  • RACSF-1 antagonists masitinib, FPA-008, JNJ-27301937, JNJ-40346527, PLX-5622, CT-1578, PD- 360324, or JNJ-28312141; CSF-1 antagonists/Fyn tyrosine kinase inhibitors/Kit tyrosine kinase inhibitors/Lyn tyrosine kinase inhibitors/NK cell receptor modulators/PDGF receptor antagonists, such as masitinib; CXC10 chemokine ligand inhibitors, such as 946414-98-8 or BMS-936557; CXCR4 chemokine antagonists, such as plerixafor; CDK-2/7/9 inhibitors/MCL1 gene inhibitors, such as seliciclib; CDK-1/2/5/7/9 inhibitors, such as BP-14; cyclooxygenase 2 inhibitors, such as celecoxib, etoricoxib, meloxicam
  • T-cell receptor ligand rheumatoid arthritis or Artielle
  • Hsp 70 family inhibitors such as gusperimus trihydrochloride
  • hypoxia inducible factor-1 inhibitors/ VEGF receptor antagonists such as 2-methoxyestradiol
  • IFNB gene stimulators such as ART-102
  • I-kappa B kinase beta inhibitors such as IMD-2560
  • I-kappa B kinase beta inhibitors/Nuclear factor kappa B inhibitors such as IMD-0560
  • IL-1 antagonists such as recombinant human interleukin-1 receptor antagonist (rheumatoid arthritis), Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • interleukin-1 beta ligand inhibitors such as gevokizumab, LY-2189102 or CDP-484; interleukin-1 beta ligand inhibitors/TNF alpha ligand inhibitors, such as PMI-001; interleukin-1 beta ligands/TNF alpha ligand modulators, such as PUR-0110; interleukin-2 ligands, such as recombinant interleukin-2; IL-2 modulators, such as AMG-592; interleukin-4 ligands/Tenascin modulators, such as Tetravil; interleukin-6 ligand inhibitors, such as gerilimzumab or PF-4236921; IRAK-4 protein kinase inhibitor, such as BAY-1830839, BAY-1834845, or PF-06650833; Itk tyrosine kinase inhibitors, such as JTE-051; Itk tyrosine kina
  • Phosphoinositide-3 kinase delta inhibitors such as CT-732, INK- 007 or GNE-293
  • Phosphoinositide-3 kinase delta/gamma inhibitors such as duvelisib or RP-6503
  • Phospholipase A2 inhibitors such as AK-106, varespladib methyl, Ro-31-4493, BM-162353, Ro-23- 9358, or YM-26734
  • Platelet activating factor receptor antagonists such as piperidone hydrochloridum
  • PPAR gamma agonists such as rosiglitazone XR
  • PPAR gamma agonists/Insulin sensitizers such as rosiglitazone
  • Programmed cell death protein 1 modulators such as INSIX RA
  • Prostaglandin D synthase stimulators such as HF-0220
  • a compound as disclosed herein such as a compound of Formula I or any formula described herein, or a pharmaceutically acceptable salt thereof, may be combined with filgotinib (GLPG0634).
  • the compounds of the disclosure may be prepared using methods disclosed herein and routine modifications thereof which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein.
  • the synthesis of typical compounds of Formula I e.g., compounds having structures described by one or more of Formula I, or other formulas or compounds disclosed herein, or a pharmaceutically acceptable salt thereof, may be accomplished as described in the following examples.
  • General Syntheses Typical embodiments of compounds in accordance with the present disclosure may be synthesized using the general reaction schemes and/or examples described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting -
  • Pure stereoisomers may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
  • the starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA).
  • solvent refers to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like).
  • solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
  • Scheme A shows an exemplary synthetic route for the synthesis of compounds provided herein (e.g., compounds of Formula I).
  • X 5 , X 7 , R 1 , R 2 , R 3 , R 4 , R 6 , R 10 , and R 11 are as defined herein
  • P 1 is hydrogen or a suitable protecting group
  • Z may be the moiety -NR 10 R 11 , or a suitable precurser thereto (e.g., a protected amino moiety, -OH or -O-alkyl, and the like)
  • LG is a leaving group
  • X and Y are each, respectively, suitable complimentary functional groups capable of forming a covalent bond therebetween.
  • a compound A-100 can first be deprotected as needed and then reacted with a compound of formula LG-R 4 , where LG is a leaving group (e.g., halo), under suitable conditions to provide compound A-101.
  • LG is a leaving group (e.g., halo)
  • Compound A-101 can then be converted to compound A-103 upon contact with a compound of formula Y-R 6 under suitable coupling conditions.
  • compound A-100 can be reacted with a compound of formula Y-R 6 under suitable coupling conditions to provide compound A-102.
  • Exemplary functional groups, and well as other functional group modifications, are detailed in the Schemes and Procedures below.
  • compound A-103 can be further modified to install the -NR 10 R 11 moiety and thus provide compounds of Formula I.
  • Z is - -NR 10 R 11 .
  • Z is suitable precurser (e.g., -OH or -O-alkyl, and the like), to Z is -NR 10 R 11 .
  • removal of P 1 and P 2 can be carried out using standard conditions, including TFA or HCl for -Boc or -trityl, and hydrogenolysis over a suitable catalyst (e.g., Pd/C) for -Cbz to afford amine products.
  • a suitable catalyst e.g., Pd/C
  • resolution of the isomers of Formula I, or any intermediate used in the preparation thereof can be performed as needed using standard chiral separation/resolution conditions (e.g., chromatography, crystallization, etc.).
  • Scheme A-1 depicts the preparation of an indole or azaindole boronic acid or ester intermediate that contains a halogen functional handle. Step 1 describes the protection of a halogenated indole or aza-indole with P 1 .
  • Y OH
  • M-R trialkyltin, boronic acid or ester, or other suitable metal species.
  • a preferred substrate B(OR)2 group is the cyclic methyiminodiacetic acid (MIDA) derivative.
  • MIAA cyclic methyiminodiacetic acid
  • M-R’ tributyl(vinyl)tin.
  • An example intermediate prepared by this approach is I-3.
  • Scheme A-3 Scheme A-3 describes the synthesis of an acetyl containing indole or azaindole boronic ester.
  • a suitable base e.g., Et 3 N, pyridine, Hunig’s base
  • Step 3 describes the direct cyclization of the hydroxyamides described in Step 2 to imidazopyridine triflate intermediates. This may be accomplished by treatment with Tf2O in the presence of a suitable base (especially 2-methoxypyridine).
  • a suitable base especially 2-methoxypyridine
  • An example intermediate prepared by this sequence is I-13.
  • a suitable amine derivative is condensed in the presence of a Lewis acid dehydrating reagent (e.g., Ti(OiPr)4, Ti(OEt)4, CuSO4) to provide an imine followed by reduction in a second step with a suitable reducing agent (e.g., NaBH4, L- selectride).
  • a Lewis acid dehydrating reagent e.g., Ti(OiPr)4, Ti(OEt)4, CuSO4
  • a suitable reducing agent e.g., NaBH4, L- selectride.
  • Scheme D-7 describes the synthesis of sulfonamide-containing R6 groups. This may be accomplished amino group with a sulfonyl chloride (e.g., methanesulfonyl chloride) and a suitable base (e.g. triethylamine).
  • Scheme D-8 Scheme D-8 describes the derivatization of an amine-containing R6 group to install substituent R 15 . This may be accomplished by treatment with a suitable alkyl, aryl, or heteroaryl halide or pseudohalide (e.g., triflate) in the presence of base to provide the product by direct nucleophilic substitution.
  • Lewis acid promoters e.g., BF3•OEt2, AlMe3, etc.
  • a suitable promoter is used to facilitate the reaction (e.g., tetrabutylammonium difluorotriphenylsilicate, tetraalkylammonium fluoride, etc.)
  • Scheme E-1 describes the installation of -N(R 10 )(R 11 ) groups via amide bond formation. Step 1 describes the hydrolysis of an ester motif to afford the corresponding carboxylic acid.
  • Step 2 shows the preparation of compounds of Formula I or precursors thereof via amide bond forming chemistry. Suitable coupling conditions, reagents and/or catalysts are well known in the art.
  • the compounds provided in Table 1 may be a single enantiomer (e.g., (S)-enantiomer, (R)-enantiomer), or the compounds may be present in a racemic or scalemic composition having one or more diastereomers or enantiomers as mixture.
  • SYNTHESIS OF INTERMEDIATES A1.01 TO A13 The following intermediates were purchased from various vendors: -
  • Step 1 The HCl salt of tert-butyl ((1R,4S)-7-azabicyclo[2.2.1]heptan-2-yl)carbamate (60.2 g, 242 mmol, commercially available as [2098589-07-0]) was dissolved in 100 mL water. To this was added a solution of sodium carbonate (38.5 g, 363 mmol) in 200 mL water, producing a voluminous white precipitate. The reaction was extracted into EtOAc (4 x 200 mL), dried over Na2SO4, filtered, and concentrated to give the free base. This material is commercially available as [2098589-06-9]. Step 2.
  • the second eluting isomer was determined to be tert-butyl (1R,2R,4S)-2-(((benzyloxy)carbonyl)amino)-7-azabicyclo[2.2.1]heptane-7-carboxylate.
  • Step 2 tert-butyl (1R,2R,4S)-2-(((benzyloxy)carbonyl)amino)-7-azabicyclo[2.2.1]heptane-7- carboxylate (46 mg, 0.13 mmol) was dissolved in dioxane.4 M hydrochloric acid in dioxane (2 mL) was added, and the resulting mixture was stirred at ambient temperature for 1 h.
  • tert-butyl rac-(1R,2R,5R)-2-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (from Synthonix) (5.08 g, 22.4 mmol) was dissolved in DCM (125 mL). Aqueous NaOH (1 M, 224 mL, 224 mmol) was added followed by benzyl chloroformate (11.1 mL, 79 mmol). The mixture was stirred for 18 h, and the phases were separated and extracted with DCM. The combined organic phase was dried over Na 2 SO 4 , filtered, and concentrated.
  • Step 3 A solution of hydrochloric acid in dioxane (4M, 54 mL, 216 mmol) was added and the resulting mixture was stirred 18 h. The mixture was concentrated to afford a crude product that was used in Step 3. Step 3.
  • the product from Step 2 was subjected to preparative SFC chromatography using a Chiral Technologies Chiralpak IC SFC column (5 ⁇ M, 4.6 x 100 mm) with a 30% MeOH eluent, using multiple injections. The slower-eluting peak was confirmed to be benzyl ((1R,2R,5S)-8- azabicyclo[3.2.1]octan-2-yl)carbamate.
  • tert-butyl ((2R,3R)-2-methylpiperidin-3-yl)carbamate (A6) Step 1. Benzyl (2R,3R)-3-amino-2-methyl-piperidine-1-carboxylate (from Synthonix) (7.4 g, 21 mmol) was dissolved in DCM (100 mL). Hunig’s base (6.5 mL, 42 mmol) was added followed by tert- butoxycarbonyl tert-butyl carbonate (4.5 g, 21 mmol). The reaction mixture was stirred 24 h and was then partitioned between DCM and aq. HCl. The phases were separated, and the aqueous phase was extracted with DCM.
  • Step 4 To a solution of benzyl (R)-2-(2-((tert-butoxycarbonyl)amino)-4-hydroxybutyl)-1- methylhydrazine-1-carboxylate (2.5 g, 6.8 mmol) and EtN(i-Pr)2 (1.77 ml, 10.21 mmol) in dichloromethane (30 mL) was added triethylsilyl trifluoromethanesulfonate (2.15 ml, 9.53 mmol) at -78 oC. The mixture was warmed to ambient over 1 h. The mixture was washed with water (30 mL) and the organic layer was dried with Na2SO4, filtered, and concentrated under vacuum.
  • the product was purified by silica chromatography using ethyl acetate in hexane.
  • the partially purified product was refluxed in methanol for 1 h.
  • the mixture was concentrated under vacuum and repurified by silica chromatography using ethyl acetate in hexane to afford benzyl (R)-2-(2-((tert-butoxycarbonyl)amino)-4- ((triethylsilyl)oxy)butyl)-1-methylhydrazine-1-carboxylate.
  • 6-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine (900.0 g, 3.07 mol, 1.0 eq) was taken up in dioxane (18 L).
  • the reaction mixture was degassed by N 2 bubbling for 10 minutes before 1-ethoxyvinyltributylstannane (2220.6 g, 6.15 mol, 2.0 eq) and PdCl 2 (dppf) (269.9 g, 369 mmol, 12 mol%) were added and the resulting mixture was heated to 100 °C.
  • Methyl 2-chloro-6-methoxyisonicotinate (10 g, 50 mmol), Pd 2 (dba) 3 (900 mg, 1.0 mmol), Xantphos (1150 mg, 1.99 mmol), and cesium carbonate (33 g, 100 mmol) were taken up in 1,4-dioxane (300 mL) under N 2 .
  • Benzophenone imine (9.6 mL, 57 mmol) was added, and the resulting mixture was stirred at 90 °C for 16 h. The mixture was then cooled and partitioned between EtOAc and water. The phases were separated, and the organic phase was washed with brine, dried over Na 2 SO 4 , filtered, and concentrated.
  • Oxalyl chloride (1.20 mL, 14.2 mmol) was added dropwise and the reaction mixture was stirred for 30 minutes, then warmed to rt and stirred for 20 minutes. After cooling in an ice bath, methyl 2-aminoisonicotinate (1530 mg, 10.1 mmol), pyridine (2.46 mL, 30.5 mmol), and 4-(Dimethylamino)pyridine (120 mg, 0.982 mmol) were added as a suspension in DCM and the reaction mixture was warmed to rt. After 40 minutes, the reaction mixture was diluted with MeOH and citric acid. After 90 minutes, the reaction mixture was partitioned between DCM and water. The layers were separated and the aqueous extracted with DCM.
  • N-iodosuccinimide (1.35 g, 6.00 mmol) was added to a solution of methyl 2- chloroimidazo[1,2-a]pyridine-7-carboxylate (1.04 g, 4.94 mmol) in acetonitrile (50 mL).
  • the reaction mixture was stirred at rt. After 90 minutes, the reaction mixture was diluted with 10% Na 2 S 2 O 3 (aq) solution (45 mL) and water (45 mL), precipitating a solid.
  • the resulting mixture was filtered and the was washed with water and dried in vacuo to yield methyl 2-chloro-3-iodoimidazo[1,2-a]pyridine-7- carboxylate I-17.
  • Lithium hydroxide monohydrate (96 mg, 2.29 mmol) was added to a mixture of methyl 2-(1-(cyclopropylmethyl)-6-(N-(difluoromethyl)methylsulfonamido)-1H-pyrrolo[2,3-b]pyridin-2-yl)-5- methoxy-3-methylimidazo[1,2-a]pyridine-7-carboxylate I-21d (365 mg, 0.684 mmol) in THF (10 mL), MeOH (5 mL), and water (5 mL) at rt. The reaction mixture was heated at 45 °C for 2.5 hours.
  • the reaction mixture was heated at 100 °C for 1 hour. After cooling to rt, it was diluted with EtOAc and water and the resulting layers were separated. The aqueous was extracted with EtOAc. The combined organics were dried (Na2SO4), filtered, and concentrated under reduced pressure. The resulting residue was purified via silica gel column chromatography (20-80% ethyl acetate in hexanes) to yield methyl 2-[1-(cyclopropylmethyl)-6-vinyl-pyrrolo[2,3-b]pyridin-2-yl]-5-methoxy-3- methyl-imidazo[1,2-a]pyridine-7-carboxylate I-22a.
  • the organic phase was dried over MgSO4, filtered, and concentrated to crude solid.
  • the solid was slurried in 30 mL hexanes for 30 min, and the mixture was filtered to collect solids.
  • the filter cake was slurried in ⁇ 30 mL hexanes for 30 minutes and the mixture was filtered to collect methyl 2-(6-acetyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H- pyrrolo[2,3-b]pyridin-2-yl)-5-methoxy-3-methylimidazo[1,2-a]pyridine-7-carboxylate I-30a, which was used without further purification for the next step.
  • Titanium (IV) ethoxide* (5.2 mL, 25 mmol, 6 equiv.) was added, and the resulting stirred mixture was heated at 60 °C. After 18 h, the reaction mixture was poured into a vigorously stirred mixture of brine (150 mL) and -
  • Isopropyl (R)-2-(6-(1-(((benzyloxy)carbonyl)amino)ethyl)-1H-pyrrolo[2,3-b]pyridin-2- yl)-3-cyclopropylimidazo[1,2-a]pyridine-7-carboxylate I-32 was prepared following step 5 and Part B of step 6 of I-31.
  • reaction mixture was diluted with water, and the precipitated solid was filtered, washed with water, and dried in vacuo.
  • an aqueous workup followed by optional purification by silica gel chromatography could be used to provide the amide product.
  • This resulting product was dissolved in acetonitrile (15 mL) and a solution of hydrogen chloride in dioxane (4 M, 2.40 mL, 9.60 mmol) was added.
  • the reaction mixture was heated to 100 °C and was stirred for 3 hours and was then diluted with water and ethyl acetate. The layers were separated and the aqueous was extracted with ethyl acetate. The combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated under reduced pressure. The resulting residue was dissolved in DCM (2 mL) and TFA (1.00 mL, 0.0131 mol) was added.
  • Steps 2-3 To a mixture of the crude products above in THF (2 mL) at 0 °C was added sodium hydride (60.0% in mineral oil, 3.7 mg, 0.092 mmol). After 30 minutes, the reaction mixture was quenched with cold sat. NH4Cl (aq) and diluted with ethyl acetate. The layers were separated, and the organics dried, filtered, and concentrated under reduced pressure. The resulting residue was dissolved in 20% TFA in DCM and after one hour, concentrated under reduced pressure.
  • reaction mixture was diluted with ethyl acetate and NH 4 Cl (aq). The layers were separated and the aqueous extracted with ethyl acetate. The combined organics were washed with sat. NaHCO3 (aq), brine, dried, filtered, and concentrated under reduced pressure. The resulting residue was dissolved in acetonitrile (3 mL) and a solution of hydrogen chloride in dioxanes (4N, 1.5 mL, 6.0 mmol) was added.
  • PAD4 BAEE Biochemical Assay The enzymatic activity of human PAD4 was monitored in a biochemical assay in the presence or absence of compounds using the small peptidyl arginine mimic BAEE (N ⁇ -Benzoyl-L-arginine ethyl ester hydrochloride) as substrate. PAD4 activity led to deimination of BAEE and release of ammonia. Levels of ammonia were monitored by using an amine coupling reaction and were indicative of PAD4 enzymatic activity. One hundred nanoliters of test compounds dissolved in DMSO at various concentrations were dispensed into a 384-well black OptiPlate using a Labcyte Echo instrument.
  • reaction mixture was incubated at 25 °C for 2 hours and was stopped with the addition of 10 microliters of a solution of 75 mM EDTA (Ethylenediaminetetraacetic acid) in PAD4 assay buffer. Thirty microliters of detection solution (5 mM o-phthalaldehyde, 50 mM MOPS [3-(N-morpholino) propanesulfonic acid], pH 7.6; 50 mM sodium chloride; 0.05% Tween-20; 5 mM dithiothreitol) was then added and the reaction was incubated for 1 hour at 25 °C.
  • detection solution 5 mM o-phthalaldehyde, 50 mM MOPS [3-(N-morpholino) propanesulfonic acid], pH 7.6; 50 mM sodium chloride; 0.05% Tween-20; 5 mM dithiothreitol
  • the level of fluorescent thiol-substituted isoindole resulting from the reaction of ammonia, o-phthalaldehyde, and dithiothreitol was measured on an Envision plate reader (PerkinElmer) with 405 nm excitation and 535 nm emission. Data were normalized based on maximum inhibition (50 micromolar of the covalent PAD inhibitor BB-Cl-Amidine (Bicker, K. L.; Anguish, L.; Chumanevich, A. A.; Cameron, M. D.; Cui, X.; Witalison, E.; Subramanian, V.; Zhang, X.; Chumanevich, A. P.; Hofseth, L.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux composés destinés à être utilisés dans le traitement thérapeutique d'une maladie associée à des peptidylarginine déiminases (PAD), telles que la peptidylarginine déiminase de type 4 (PAD4). La présente invention concerne également des procédés et des intermédiaires pour la préparation de tels composés, des procédés d'utilisation de tels composés et des compositions pharmaceutiques comprenant les composés décrits ici.
EP21848379.0A 2020-12-22 2021-12-21 Inhibiteurs de peptidylarginine déiminases Pending EP4267587A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063129421P 2020-12-22 2020-12-22
PCT/US2021/064669 WO2022140428A2 (fr) 2020-12-22 2021-12-21 Inhibiteurs de peptidylarginine déiminases

Publications (1)

Publication Number Publication Date
EP4267587A2 true EP4267587A2 (fr) 2023-11-01

Family

ID=80050784

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21848379.0A Pending EP4267587A2 (fr) 2020-12-22 2021-12-21 Inhibiteurs de peptidylarginine déiminases

Country Status (4)

Country Link
US (1) US20220227787A1 (fr)
EP (1) EP4267587A2 (fr)
TW (1) TW202233174A (fr)
WO (1) WO2022140428A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024064726A1 (fr) * 2022-09-21 2024-03-28 Bristol-Myers Squibb Company Procédé de préparation de tert-butyl(2-azabicyclo[2.2.1]heptan-4-yl)carbamate et composés associés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2152701T3 (en) 2007-03-12 2016-02-15 Ym Biosciences Australia Pty Phenylaminopyrimidinforbindelser and uses thereof
SG11202003463XA (en) * 2017-10-18 2020-05-28 Jubilant Epipad LLC Imidazo-pyridine compounds as pad inhibitors
EP3833440A1 (fr) * 2018-08-08 2021-06-16 Bristol-Myers Squibb Company Inhibiteurs indoles et azaindoles d'enzymes pad
EP4267562A1 (fr) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibiteurs de peptidylarginine déiminases

Also Published As

Publication number Publication date
WO2022140428A2 (fr) 2022-06-30
WO2022140428A3 (fr) 2022-08-04
TW202233174A (zh) 2022-09-01
US20220227787A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP7041198B2 (ja) Ｊａｋ阻害剤である５－クロロ－２－ジフルオロメトキシフェニルピラゾロピリミジン化合物
JP7376218B2 (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
JP7264060B2 (ja) 二環式化合物および癌の処置におけるそれらの使用
JP2019218387A (ja) キナーゼ調節のための化合物と方法、及びそのための適応
AU2021265110B2 (en) Macrocyclic inhibitors of peptidylarginine deiminases
TW200302725A (en) N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
TW201313716A (zh) 作為ｃ－ｋｉｔ激酶抑制劑之化合物及組合物
TW202122397A (zh) Ｒｉｐ１抑制性化合物及用於製備和使用其之方法
TW202204364A (zh) Rip1k抑制劑
JP2020520957A (ja) 処置用化合物及び組成物、並びにその使用方法
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
EP4267587A2 (fr) Inhibiteurs de peptidylarginine déiminases
JP2021510693A (ja) Ｊａｋ阻害剤としてのピラゾロピリミジン化合物
EP4267562A1 (fr) Inhibiteurs de peptidylarginine déiminases
JP7050761B2 (ja) ８－（アゼチジン－１－イル）－［１，２，４］トリアゾロ［１，５－ａ］ピリジニル化合物、組成物及びその使用方法
JP7493586B2 (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
TWI840311B (zh) Rip1k抑制劑
CN117957234A (zh) 噻吩并吡咯化合物
TW202408480A (zh) Rip1k抑制劑
TW202342013A (zh) 雜環化合物、其組成物及用其進行治療之方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230719

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)